TLRY Tilray Inc

$10.09
$0.01 (0.10%)

TLRY Stock Analysis Overview

What this means: InvestorsObserver gives Tilray Inc (TLRY) an overall rank of 30, which is below average. Tilray Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 30 means that 70% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full TLRY report

Tilray Inc (TLRY) Analyst Forecast

Next 12 months ➝Current Price$10.0952-week High$51.0352-week Low$2.43MEAN$10.94+8.46%HIGH$26.00+157.68%LOW$2.00-80.18%
  • Last Price$10.09
  • Previous Close$10.08
  • Change $0.01
  • Open$10.13
  • Volume7,000,813
  • Avg. Volume (100-day)10,466,684
  • Market Capitalization$1B
  • Days Range $9.91 - $10.31
  • 52-week Range $2.43 - $51.03
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-4.61
  • Earnings Date08/11/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • Avg. Analyst Rec.
  • Beta0.311
  • PEG Ratio
  • Volatility0.90
  • Average True Range0.15
Tilray, headquartered in Nanaimo, Canada, cultivates and sells medical and recreational cannabis through a portfolio of brands that include Canaca, Dubon, and Manitoba Harvest. The bulk of Tilray's sales are in Canada, but the company also sells CBD Products in the U.S. and exports medical cannabis globally from its production facilities in Canada and Portugal. Tilray also has a joint venture partnership with AB InBev to develop cannabis-infused drinks.